FDA Approves First-in-Class Non-Opioid Pain Reliever
Journavx (suzetrigine) – a first-in-class, non-opioid analgesicA new non-opioid pain treatment option
On January 30, 2025, the FDA granted priority review for Journavx (suzetrigine) – a first-in-class, non-opioid analgesic for treating moderate to severe acute pain in adults.
How It Works
Journavx targets sodium channels in the peripheral nervous system, interrupting pain signals before they reach the brain — offering a novel mechanism of action with no opioid involvement.
Key Trial Results
- Evaluated in two surgical pain studies (abdominoplasty and bunionectomy).
- Patients using Journavx had significantly better pain relief than those on placebo.
- Common side effects: itching, muscle spasms, rash, and elevated creatine phosphokinase.
Warnings
Users should avoid grapefruit and strong CYP3A inhibitors due to interaction risk.
Why It Matters
This marks the first approval in a new class of non-opioid pain medicines, aligning with the FDA’s push to expand safer alternatives amid the opioid crisis.
Approved by: Vertex Pharmaceuticals
Designations: Breakthrough Therapy, Fast Track, Priority Review
Journavx offers a promising new option for acute pain relief — without the risks of opioids.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA Approves XACT Carotid Stent System
A Breakthrough for Stroke Prevention Abbott Vascular Inc. has received FDA approval for its groundbreaking XACT Carotid Stent System, a significant advancement in stroke prevention technology. Approved on February 7, 2024, this innovative system offers new hope for...
FDA Approves Xolremdi for WHIM Syndrome
A Breakthrough for Rare Infections In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted approval for Xolremdi (mavorixafor) capsules, marking a significant milestone in the treatment of WHIM syndrome. Let's delve into what this...
FDA Fast Track Program
For Serious Conditions - Unmet Medical Needs The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs and biologics intended to treat serious conditions and fill an unmet medical need. Following are key details of the...